Humira Biosimilar Transition: What to Do
Humira Biosimilar Transition: What to Do
96% of Humira Patients Were Switched to a Biosimilar. Here Is What That Means If You Were One of Them.
5 minute read
CVS Health announced that approximately 96 percent of its Humira (adalimumab) patients have been transitioned to biosimilar versions of the medication.¹ That number is not a projection. It reflects a real transition that happened largely through formulary management, meaning plans restructured their coverage in ways that made biosimilars the default path and made continuing on the reference biologic significantly more expensive or unavailable.
If you are among the patients who experienced this transition and you are having problems, whether disease flares, injection site reactions, or simply the frustration of never being asked, it helps to understand exactly what happened and what your options are now. And if you are still on Humira and wondering whether a switch is coming for you, this is useful information to have in advance.
What "Interchangeable" Actually Means
When the FDA designates a biosimilar as "interchangeable," it means the agency has determined that the biosimilar can be substituted for the reference biologic at the pharmacy level without involving the prescriber. This is a higher bar than basic biosimilar approval. To earn an interchangeability designation, a manufacturer must demonstrate through switching studies that patients can alternate between the biosimilar and the reference product without increased safety or efficacy risk.²
Several adalimumab biosimilars have received interchangeable designation from the FDA. This designation is what allows a pharmacist in most states to substitute one of these biosimilars for a Humira prescription without calling your doctor first.
But "interchangeable" in the FDA sense does not mean your insurer required a switch. The formulary transition that CVS Caremark and other plan administrators have conducted is a separate decision made for coverage and cost reasons. It operates through the formulary, not through the pharmacy substitution rules. The result is similar from your perspective: the drug that arrives may not be what your physician originally prescribed. But the mechanism matters when you think about how to respond.
Interchangeable vs. Substitutable: The Distinction That Matters for Your Appeal
These two terms are often used interchangeably (no pun intended) but they are legally distinct.
FDA interchangeability is a regulatory designation. It authorizes substitution at the pharmacy level under state substitution laws, without prescriber sign-off, when a pharmacist is filling a prescription for the reference biologic.
Formulary substitution is an insurance coverage decision. Your plan decides which adalimumab product it will cover on which tier, and if the reference Humira is no longer on a covered tier, the practical effect is a switch, but it is driven by coverage rules, not pharmacy substitution law.
The reason this distinction matters: if you are experiencing problems after a formulary-driven transition to a biosimilar, your physician needs to document that your current clinical status is being managed on the biosimilar and note any issues. That documentation supports a medical exception request to return to the reference product. The exception request should address the plan's coverage criteria for the reference biologic and explain why the biosimilar is not clinically appropriate for your individual situation.
State substitution laws typically also require that the prescriber be notified when a biosimilar is substituted for a reference biologic. If you were switched and your prescribing physician was not informed, your state's pharmacy notification requirements may have been violated, which is relevant context for any appeal.
If You Were Switched and Your Condition Changed
Disease flares, worsening inflammation, or unexpected side effects after a non-medical switch are not uncommon topics in the rheumatology and gastroenterology literature. The frequency and clinical significance of these events are debated, and for many patients the biosimilar works as well as the reference product. But for patients who were doing well on the original medication and experienced a change after switching, that clinical story matters.
Document everything. Contact your physician immediately if your condition has changed since the switch. Ask your physician to note in your medical record the timeline of the switch and any changes in disease activity, laboratory values, or clinical symptoms following the transition.
This documentation is the core of your appeal. An exception request that says "I was switched and something feels different" is less likely to succeed than a request that says "the patient had documented disease stability for two years on the reference biologic, was transitioned to biosimilar X on a specific date, and subsequently experienced documented flare activity requiring clinical intervention."
What This Means for You
If you are on an adalimumab biosimilar and doing well, you likely do not need to take any action. Biosimilars that have FDA approval are considered safe and effective, and for many patients the transition has been medically unremarkable.
If you are on an adalimumab biosimilar and your condition has changed, call your physician this week. Get the change documented. Ask your physician whether a medical exception request for the reference product is appropriate given your clinical history.
If you are still on reference Humira and you receive a notice that your plan is changing its coverage, read the notice carefully. You have the right to a transition supply and the right to request a formulary exception before the change takes effect. Your physician's documentation, prepared in advance, gives you the best position when filing that exception.
If your exception request is denied, you have the right to appeal. At the appeal level, an independent external reviewer who is not employed by your insurer will review your clinical case.
Ellen can help you understand your denial and build your appeal. Start here
Frequently Asked Questions
Does my doctor have to approve a biosimilar switch?
If the switch happens through formulary management (your plan stops covering the reference biologic at the same level), your physician does not need to formally approve the coverage change. However, your physician can file a medical exception request on your behalf if there is a clinical reason to continue the reference product. If the switch happened at the pharmacy level under a state substitution law, most states require that the prescriber be notified.
I was switched without anyone asking me. Is that legal?
Mid-year formulary changes are subject to notice requirements. If your plan changed its coverage of Humira mid-year without adequate notice, you may have transition protections available. For pharmacy-level substitutions of interchangeable biosimilars, state laws vary on whether patient notification is required in addition to prescriber notification. If you believe the substitution was made without proper notification, contact your state insurance commissioner's office.
What if I tried the biosimilar and it did not work?
If you have tried a biosimilar and had a documented therapeutic failure (your condition worsened or you had an adverse reaction), that documented therapeutic failure is powerful evidence in a medical exception request or appeal for coverage of the reference biologic. Ask your physician to create a clear record of the failure, including dates, clinical measurements where applicable, and the physician's clinical assessment.
Sources: